BioFiles Volume 7, Number 5 — Pharmaceutical Drugs and Drug Candidates

Download BioFiles v7 n5 (3.18 Mb PDF)


Pharmaceutical Drugs and Drug CandidatesTable of Contents



Sami Barghshoon

The development of effective medications has led to progress in controlling both blood pressure and cholesterol level.1-2 Antihypertensive and antilipemic agents have vastly improved the treatments available for hypertension and the quality of life of individuals with this condition.

In 2011, there were 299 drug candidates under development and 5,701 clinical trials (Open Studies only) worldwide.3-4 From this group, 27 drug candidates are under evaluation for hypertension in 664 clinical trials and 43 candidates in 103 clinical trials for lipid disorders.

The majority of hypertension clinical trials focus on combination therapies while lipid disorders examine the combination of lifestyle and medication intervention on managing the disease.

Much of the groundwork for approved therapeutics and drug candidates under development came from extensive basic research in hypertension.5 Researchers are continually working to discover new ways to approach the R&D process; researchers must creatively tackle unforeseen challenges and thoroughly collect data on all aspects of the drug’s safety and efficacy.

We are currently collaborating with Pfizer to provide you access to several of their approved therapeutics and drug candidates for your research efforts. Our bioactive small molecules portfolio also extends to include compounds from GSK, Merck &Co., AstraZeneca, and more.

We work closely with academic and government institutions. Along with your peers from the Broad Institute and Northeastern University, we select compounds to provide you with the latest and most relevant research tools for evaluating drug targets for the study of hypertension.

By ensuring a comprehensive portfolio, we make it easier for you to find the needed approved therapeutics and drug candidates for cardiovascular research. That means your flashes of inspiration and persistent dedication might lead to new treatments for hypertension sooner than you expected.

This Biofiles issue concentrates on our selection of approved therapeutics and drug candidates for hypertension. Our portfolio includes antihypertensive agents such as:

  • Angiotensin converting enzyme inhibitors
  • Angiotensin receptor blockers
  • β-adrenoreceptor blockers
  • Calcium channel blockers
  • Thiazide diuretics

We also explore antilipemic—HMG-CoA reductase and ACAT inhibitors—and anticoagulant agents. Complementary products such as antibodies, peptides, biomolecules (naturally-derived compounds), and zinc finger nucleases are included.

And we don’t offer a “one size fits all.” We offer a host of products and services to support your research, including our Library of Pharmacologically Active Compounds LOPAC® and MISSION® ID Library for gene target identification. We aim to provide elegant solutions that are tailored to your specific research needs.

Basic and clinical research continue to make remarkable progress in understanding cardiovascular biology. At the heart of this progress is our commitment to provide you with the best tools to do your best work in advancing the promise of science.


  1. Roger et al. 2011. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 123:e18-e209.
  2. Arima, H. and Chalmers, J. 2011. PROGRESS: Prevention of recurrent stroke. J Clin Hypertens 13:693-702.
  3. PhRMA. 2011. Medicines in development for heart disease and stroke.
  4. NIH. 2011. Clinical Trials: Open studies in cardiovascular disease.
  5. PhRMA. 2011. Pharmaceutical industry profile.

back to Biofiles homepage
back to top